Several other equities analysts have also issued reports on NBIX. BidaskClub upgraded Neurocrine Biosciences from a hold rating to a buy rating in a research note on Thursday, January 4th. Deutsche Bank restated a buy rating and set a $79.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Citigroup restated a buy rating and set a $79.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Jefferies Group boosted their price target on Neurocrine Biosciences to $105.00 and gave the company a buy rating in a research note on Friday, January 5th. Finally, Robert W. Baird restated a buy rating and set a $84.00 price target on shares of Neurocrine Biosciences in a research note on Friday, November 3rd. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Neurocrine Biosciences presently has a consensus rating of Buy and a consensus target price of $82.31.
Shares of Neurocrine Biosciences (NASDAQ:NBIX) traded up $2.37 on Monday, reaching $81.37. The company had a trading volume of 895,500 shares, compared to its average volume of 1,104,111. Neurocrine Biosciences has a 1 year low of $38.43 and a 1 year high of $83.84. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $7,200.00, a price-to-earnings ratio of -36.65 and a beta of 0.35.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million for the quarter, compared to the consensus estimate of $29.38 million. During the same quarter in the prior year, the firm earned ($0.43) earnings per share. equities research analysts expect that Neurocrine Biosciences will post -1.61 earnings per share for the current fiscal year.
In other news, insider Dimitri E. Grigoriadis sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $74.58, for a total value of $2,237,400.00. Following the transaction, the insider now directly owns 77,691 shares of the company’s stock, valued at approximately $5,794,194.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Darin Lippoldt sold 9,900 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $73.05, for a total value of $723,195.00. The disclosure for this sale can be found here. Insiders have sold 116,405 shares of company stock worth $8,588,519 over the last ninety days. Company insiders own 4.80% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company boosted its holdings in shares of Neurocrine Biosciences by 7.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after acquiring an additional 193 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in shares of Neurocrine Biosciences by 0.7% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 120,426 shares of the company’s stock worth $7,380,000 after acquiring an additional 810 shares in the last quarter. Mutual of America Capital Management LLC boosted its holdings in shares of Neurocrine Biosciences by 0.9% in the 3rd quarter. Mutual of America Capital Management LLC now owns 112,862 shares of the company’s stock worth $6,916,000 after acquiring an additional 1,036 shares in the last quarter. Grandfield & Dodd LLC boosted its holdings in shares of Neurocrine Biosciences by 24.1% in the 3rd quarter. Grandfield & Dodd LLC now owns 7,610 shares of the company’s stock worth $466,000 after acquiring an additional 1,480 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Neurocrine Biosciences by 51.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,704 shares of the company’s stock worth $288,000 after acquiring an additional 1,599 shares in the last quarter.
TRADEMARK VIOLATION NOTICE: “Oppenheimer Reiterates $95.00 Price Target for Neurocrine Biosciences (NBIX)” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://transcriptdaily.com/2018/01/16/oppenheimer-reiterates-95-00-price-target-for-neurocrine-biosciences-nbix.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.